Ischemic Heart Disease Market
Global Ischemic Heart Disease Market Research By Disease Type (Angina, Myocardial Infarction and Ischemic Stroke), By Diagnosis Method (Electrocardiogram (ECG), Echocardiogram, Chest X-Ray, Cardiac Catheterization and Coronary Angiogram), and By Treatment (Medication and Surgery) Forecast Period 2021-2027 Update Available - Forecast 2024-2030
The global ischemic heart disease market is growing at a considerable CAGR of 4.7% during the forecast period. Increasing pervasiveness of cardiovascular diseases among people across the globe is one of the prime factors affecting and driving the market. Increasing population having high cholesterol along with obesity, and accessibility of effective surgical treatments is also estimated to be the prime factors that are contributing significantly towards the growth of the market. However, rising uncertainty related with reimbursement policy along with high cost involvement are some major factors constraints that are hindering the growth of the global ischemic heart disease market across the globe.
However, government initiative along with funding and rising awareness towards various heart diseases is one of the key factors that are creating opportunities for the market. New product launches in the market are likely to drive the growth of the global ischemic heart disease market. For instance, In June 2020, AstraZeneca Brilinta (ticagrelor) had received approval and clearance in the US in order to decrease the risk factor related with first heart attack or patient having high risk with coronary artery disease (CAD) which is considered to be the most common type of heart disease. This approval was being received by the company on the basis of the Phase 3 EMIS trial. The trial had given the positive result related to reduction in heart attack and stroke.
Impact of COVID-19 on the Global Ischemic Heart Disease Market
The global ischemic heart disease market is hardly hit by the COVID-19 pandemic since December 2019. The COVID-19 pandemic in the major economies had disrupted the manufacturing and transportation activities. There were disruptions in ischemic heart disease testing across the globe. All the activities related with ischemic heart disease were being reduced from disease diagnosis till treatment due to COVID-19 pandemic.
Segmental Outlook
The market is segmented based on a disease type, diagnosis method and treatment. Based on disease type, the market is segmented into angina, myocardial infarction and ischemic stroke. By diagnosis method, the market is segmented into electrocardiogram (ECG), echocardiogram, chest x-ray, cardiac catheterization and coronary angiogram. Further, by treatment, market is segmented into medication and surgery.
Global Ischemic Heart Disease Market Share by Disease Type 2020 (%)
Based on the disease type, angina hold a significant share in the market. Angina is considered as the type of heart problem in which the heart muscle does not get sufficient oxygen rich blood and it causes a chest pain. Additionally, the sense of discomfort can also be felt due to it in neck, jaw, back or even in shoulders and arms. Angina can also signify the symptoms related with Coronary Microvascular Disease (MVD).
Regional Outlooks
The global ischemic heart disease market is analyzed based on the geographical regions that are contributing significantly towards the growth of the market. Based on the geography, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America held a considerable share in 2020 in the global ischemic heart disease market. Some factors that are boosting the market growth in North America are growing pervasiveness of cardiovascular diseases, leading manufactures and players present mobility devices in the region. Additionally, favorable reimbursement along with increasing awareness related with heart disease is other factors that are promoting the growth of the market.
Global Ischemic Heart Disease Market, by Region 2021-2027
Asia-Pacific will have Considerable Growth in the Global Ischemic Heart Disease Market
Asia-Pacific region is expected to witness significant growth opportunities for the market. Increasing awareness towards coronary artery disease (CAD) along with changing lifestyle pattern that leads to unhealthy diet among people in emerging economies of the region are likely to drive the growth of the regional market. Further due to health and medical attention availability, rising health care expenditure along with increasing pervasiveness of heart diseases and strokes in India, China and South Korea are also some of the factors that are affecting and impacting the growth in this market.
Market Player Outlook
Key players of the global ischemic heart disease market are Abbott, AstraZeneca, Boston Scientific Corp., Koninklijke Philips N.V, and Sanofi among others. To survive in the market, these players adopt different marketing strategies such as product launches, collaboration and acquisition. For instance, in August 2020, Koninklijke Philips N.V that is one of the global providers of technology in healthcare sector had announced the acquisition of Intact vascular Inc. The acquired company is the US developers of medical devices and through this acquisition it will enhance the portfolio of Koninklijke Philips N.V in image-guided therapy which will support in patient’s treatment with Peripheral Artery Disease (PAD).
In November 2020, Stryker had set forth that it had completed the acquisition of wright medical group NV which is one of the medical device companies. Through this company can provide effective solution that will lead to better outcomes related with the health of patients.
In April 2019, Sanofi had received the acceptance and clearance from United States Food and Drug Administration (FDA) for praluent (Alirocumab). Praluent was prepared by collaboration between sanofi along with Regeneron which is one of the biotechnology companies in order to decrease the risk related with heart attack, strong along with unstable angina.
The Report Covers
• Market value data analysis of 2020 and forecast to 2027.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global ischemic heart disease market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global Ischemic Heart Disease Industry
• Recovery Scenario of Global Ischemic Heart Disease Industry
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of Covid-19 on Key Players
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global Ischemic Heart Disease Market by Disease Type
5.1.1. Angina
5.1.2. Myocardial Infarction
5.1.3. Ischemic Stroke
5.2. Global Ischemic Heart Disease Market by Diagnosis Method
5.2.1. Electrocardiogram (ECG)
5.2.2. Echocardiogram
5.2.3. Chest X-Ray
5.2.4. Cardiac Catheterization
5.2.5. Coronary Angiogram
5.3. Global Ischemic Heart Disease Market by Treatment
5.3.1. Medication
5.3.2. Surgery
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. South Korea
6.3.5. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Abbott
7.2. Amgen Inc.
7.3. AstraZeneca
7.4. Bayer AG
7.5. Boston Scientific Corp.
7.6. Cardinal Health
7.7. DAIICHI SANKYO CO., LTD.
7.8. Edwards Lifesciences Corp.
7.9. General Electric
7.10. Koninklijke Philips N.V
7.11. Lepu Medical Technology Co.,Ltd.
7.12. Medtronic
7.13. Merck KGaA,
7.14. Meril Life Sciences Pvt. Ltd.
7.15. Sanofi
7.16. Siemens Healthcare Pvt.Ltd.
7.17. Stryker
7.18. Terumo Corp.
7.19. W. L. Gore & Associates, Inc.
1. GLOBAL ISCHEMIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, 2020-2027
2. GLOBAL ISCHEMIC HEART DISEASE MARKET BY DISEASE TYPE, 2020-2027 ($ MILLION)
3. GLOBAL ANGINA MARKET BY REGION, 2020-2027 ($ MILLION)
4. GLOBAL MYOCARDIAL INFARCTION MARKET BY REGION, 2020-2027 ($ MILLION)
5. GLOBAL ISCHEMIC STROKE MARKET BY REGION, 2020-2027 ($ MILLION)
6. GLOBAL ISCHEMIC HEART DISEASE MARKET BY DIAGNOSIS METHOD, 2020-2027 ($ MILLION)
7. GLOBAL ELECTROCARDIOGRAM (ECG) MARKET BY REGION, 2020-2027 ($ MILLION)
8. GLOBAL ECHOCARDIOGRAM MARKET BY REGION, 2020-2027 ($ MILLION)
9. GLOBAL CHEST X-RAY MARKET BY REGION, 2020-2027 ($ MILLION)
10. GLOBAL CARDIAC CATHETERIZATION MARKET BY REGION, 2020-2027 ($ MILLION)
11. GLOBAL CORONARY ANGIOGRAM MARKET BY REGION, 2020-2027 ($ MILLION)
12. GLOBAL ISCHEMIC HEART DISEASE MARKET BY TREATMENT, 2020-2027 ($ MILLION)
13. GLOBAL MEDICATION MARKET BY REGION, 2020-2027 ($ MILLION)
14. GLOBAL SURGERY MARKET BY REGION, 2020-2027 ($ MILLION)
15. GLOBAL ISCHEMIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
16. NORTH AMERICAN ISCHEMIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
17. NORTH AMERICAN ISCHEMIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2020-2027 ($ MILLION)
18. NORTH AMERICAN ISCHEMIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2020-2027 ($ MILLION)
19. NORTH AMERICAN ISCHEMIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
20. EUROPEAN ISCHEMIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
21. EUROPEAN ISCHEMIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2020-2027 ($ MILLION)
22. EUROPEAN ISCHEMIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2020-2027 ($ MILLION)
23. EUROPEAN ISCHEMIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
24. ASIA-PACIFIC ISCHEMIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
25. ASIA-PACIFIC ISCHEMIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2020-2027 ($ MILLION)
26. ASIA-PACIFIC ISCHEMIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2020-2027 ($ MILLION)
27. ASIA-PACIFIC ISCHEMIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
28. REST OF WORLD ISCHEMIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2020-2027 ($ MILLION)
29. REST OF WORLD ISCHEMIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2020-2027 ($ MILLION)
30. REST OF WORLD ISCHEMIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL ISCHEMIC HEART DISEASE MARKET, 2020-2027 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL ISCHEMIC HEART DISEASE MARKET SHARE BY SEGMENT, 2020-2027 ($ MILLION)
3. RECOVERY OF GLOBAL ISCHEMIC HEART DISEASE MARKET, 2021-2027 (%)
1. GLOBAL ISCHEMIC HEART DISEASE MARKET SHARE BY DISEASE TYPE, 2020 VS 2027 (%)
2. GLOBAL ISCHEMIC HEART DISEASE MARKET SHARE BY DIAGNOSIS METHOD, 2020 VS 2027 (%)
3. GLOBAL ISCHEMIC HEART DISEASE MARKET SHARE BY TREATMENT, 2020 VS 2027 (%)
4. GLOBAL ISCHEMIC HEART DISEASE MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
5. GLOBAL ANGINA MARKET BY REGION, 2020 VS 2027 (%)
6. GLOBAL MYOCARDIAL INFARCTION MARKET BY REGION, 2020 VS 2027 (%)
7. GLOBAL ISCHEMIC STROKE MARKET BY REGION, 2020 VS 2027 (%)
8. GLOBAL ELECTROCARDIOGRAM (ECG) MARKET BY REGION, 2020 VS 2027 (%)
9. GLOBAL ECHOCARDIOGRAM MARKET BY REGION, 2020 VS 2027 (%)
10. GLOBAL CHEST X-RAY MARKET BY REGION, 2020 VS 2027 (%)
11. GLOBAL CARDIAC CATHETERIZATION MARKET BY REGION, 2020 VS 2027 (%)
12. GLOBAL CORONARY ANGIOGRAM MARKET BY REGION, 2020 VS 2027 (%)
13. GLOBAL MEDICATION MARKET BY REGION, 2020 VS 2027 (%)
14. GLOBAL SURGERY MARKET BY REGION, 2020 VS 2027 (%)
15. US ISCHEMIC HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
16. CANADA ISCHEMIC HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
17. UK ISCHEMIC HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
18. FRANCE ISCHEMIC HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
19. GERMANY ISCHEMIC HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
20. ITALY ISCHEMIC HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
21. SPAIN ISCHEMIC HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
22. REST OF EUROPEISCHEMIC HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
23. INDIA ISCHEMIC HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
24. CHINA ISCHEMIC HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
25. JAPAN ISCHEMIC HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
26. SOUTH KOREA ISCHEMIC HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
27. REST OF ASIA-PACIFIC ISCHEMIC HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
28. REST OF THE WORLD ISCHEMIC HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
